Pulmatrix, Inc. (PULM) stock
PULMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.37+0.04 (+3.01%)
Close on Nov 17, 2026Market cap $5.00MP/E –Yield –
Pulmatrix r&d expenses
Research and development expenses are spending on new products and technology.
Pulmatrix's R&D Expenses for the twelve months ending Sep 30, 2025 was $47.00K, down 99.6% year over year. For fiscal 2025 it was $38.00K, down 99.5% from the year before. Over ten years it grew -40.8% a year on average. The highest annual figure on record is $18.24M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.00K | -99.5% |
| FY2024 | Dec 31, 2024 | $7.17M | -53.8% |
| FY2023 | Dec 31, 2023 | $15.52M | -14.9% |
| FY2022 | Dec 31, 2022 | $18.24M | +18.6% |
| FY2021 | Dec 31, 2021 | $15.38M | -1.5% |
| FY2020 | Dec 31, 2020 | $15.61M | +21.5% |
| FY2019 | Dec 31, 2019 | $12.85M | -0.9% |
| FY2018 | Dec 31, 2018 | $12.97M | +26.6% |
| FY2017 | Dec 31, 2017 | $10.24M | +0.9% |
| FY2016 | Dec 31, 2016 | $10.15M | +41.3% |
| FY2015 | Dec 31, 2015 | $7.19M | +9.1% |
| FY2014 | Dec 31, 2014 | $6.59M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.00K | -92.9% |
| Q2 FY2026 | Jun 30, 2026 | $2.00K | -89.5% |
| Q1 FY2026 | Mar 31, 2026 | $3.00K | -50.0% |
| Q3 FY2025 | Sep 30, 2025 | $8.00K | -99.0% |
| Q2 FY2025 | Jun 30, 2025 | $14.00K | -99.5% |
| Q1 FY2025 | Mar 31, 2025 | $19.00K | -99.5% |
| Q4 FY2024 | Dec 31, 2024 | $6.00K | -99.8% |
| Q3 FY2024 | Sep 30, 2024 | $814.00K | -79.5% |
| Q2 FY2024 | Jun 30, 2024 | $2.83M | -32.0% |
| Q1 FY2024 | Mar 31, 2024 | $3.51M | -9.3% |
| Q4 FY2023 | Dec 31, 2023 | $3.52M | -21.3% |
| Q3 FY2023 | Sep 30, 2023 | $3.96M | -25.0% |
| Q2 FY2023 | Jun 30, 2023 | $4.17M | -4.0% |
| Q1 FY2023 | Mar 31, 2023 | $3.87M | -6.6% |
| Q4 FY2022 | Dec 31, 2022 | $4.47M | +51.0% |
| Q3 FY2022 | Sep 30, 2022 | $5.29M | +31.3% |
| Q2 FY2022 | Jun 30, 2022 | $4.34M | -4.5% |
| Q1 FY2022 | Mar 31, 2022 | $4.15M | +7.6% |
| Q4 FY2021 | Dec 31, 2021 | $2.96M | -9.4% |
| Q3 FY2021 | Sep 30, 2021 | $4.03M | +4.0% |
| Q2 FY2021 | Jun 30, 2021 | $4.54M | +42.6% |
| Q1 FY2021 | Mar 31, 2021 | $3.86M | -27.1% |
| Q4 FY2020 | Dec 31, 2020 | $3.27M | -22.4% |
| Q3 FY2020 | Sep 30, 2020 | $3.87M | +17.5% |
| Q2 FY2020 | Jun 30, 2020 | $3.18M | +0.6% |
| Q1 FY2020 | Mar 31, 2020 | $5.29M | +143.0% |
| Q4 FY2019 | Dec 31, 2019 | $4.21M | +30.6% |
| Q3 FY2019 | Sep 30, 2019 | $3.30M | +7.9% |
| Q2 FY2019 | Jun 30, 2019 | $3.16M | -21.2% |
| Q1 FY2019 | Mar 31, 2019 | $2.18M | -32.4% |
| Q4 FY2018 | Dec 31, 2018 | $3.22M | +24.4% |
| Q3 FY2018 | Sep 30, 2018 | $3.06M | +16.7% |
| Q2 FY2018 | Jun 30, 2018 | $4.01M | +19.3% |
| Q1 FY2018 | Mar 31, 2018 | $3.22M | +92.6% |
| Q4 FY2017 | Dec 31, 2017 | $2.59M | -6.7% |
| Q3 FY2017 | Sep 30, 2017 | $2.62M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.36M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.67M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.77M | – |
See a number that looks wrong?